ImmunoGen Inc. (NASDAQ:IMGN) went down by -6.86% from its latest closing price compared to the recent 1-year high of $10.88. The company’s stock price has collected -0.62% of loss in the last five trading sessions. Press Release reported on 04/01/21 that ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is It Worth Investing in ImmunoGen Inc. (NASDAQ :IMGN) Right Now?
Plus, the 36-month beta value for IMGN is at 1.38. Opinions of the stock are interesting as 6 analysts out of 9 who provided ratings for ImmunoGen Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $10.57, which is $2.2 above the current price. IMGN currently public float of 169.84M and currently shorts hold a 13.14% ratio of that float. Today, the average trading volume of IMGN was 2.55M shares.
IMGN’s Market Performance
IMGN stocks went down by -0.62% for the week, with a monthly drop of -10.50% and a quarterly performance of 23.33%, while its annual performance rate touched 134.21%. The volatility ratio for the week stands at 5.18% while the volatility levels for the past 30 days are set at 5.31% for ImmunoGen Inc.. The simple moving average for the period of the last 20 days is -5.96% for IMGN stocks with a simple moving average of 34.96% for the last 200 days.
Analysts’ Opinion of IMGN
Many brokerage firms have already submitted their reports for IMGN stocks, with H.C. Wainwright repeating the rating for IMGN by listing it as a “Buy.” The predicted price for IMGN in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on October 26th of the previous year 2020.
Guggenheim, on the other hand, stated in their research note that they expect to see IMGN reach a price target of $14. The rating they have provided for IMGN stocks is “Buy” according to the report published on October 02nd, 2020.
IMGN Trading at -4.92% from the 50-Day Moving Average
After a stumble in the market that brought IMGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.38% of loss for the given period.
Volatility was left at 5.31%, however, over the last 30 days, the volatility rate increased by 5.18%, as shares sank -5.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.54% upper at present.
During the last 5 trading sessions, IMGN fell by -0.62%, which changed the moving average for the period of 200-days by +75.66% in comparison to the 20-day moving average, which settled at $8.50. In addition, ImmunoGen Inc. saw 24.19% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at IMGN starting from FOSTER DAVID G, who sale 11,052 shares at the price of $6.38 back on Dec 31. After this action, FOSTER DAVID G now owns 37,912 shares of ImmunoGen Inc., valued at $70,512 using the latest closing price.
Stock Fundamentals for IMGN
Current profitability levels for the company are sitting at:
- -15.79 for the present operating margin
The net margin for ImmunoGen Inc. stands at -33.54. The total capital return value is set at -15.30, while invested capital returns managed to touch -49.49. Equity return is now at value -983.10, with -15.10 for asset returns.
Based on ImmunoGen Inc. (IMGN), the company’s capital structure generated 122.06 points at debt to equity in total, while total debt to capital is 54.97. Total debt to assets is 30.79, with long-term debt to equity ratio resting at 66.69. Finally, the long-term debt to capital ratio is 30.03.
When we switch over and look at the enterprise to sales, we see a ratio of 7.19, with the company’s debt to enterprise value settled at 0.11. The receivables turnover for the company is 5.32 and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.